Evidence map›Paper›PMID 29123160›Full record

ArticleScientific reports2017

InsuTAG: A novel physiologically relevant predictor for insulin resistance and metabolic syndrome.

Rohith N Thota, Kylie A Abbott, Jessica J A Ferguson, Martin Veysey, Mark Lucock, Suzanne Niblett, Katrina King, Manohar L Garg

Abstract readEvaluation Study
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rohith N ThotaNutraceuticals Research Program, School of Biomedical Sciences & Pharmacy, University of Newcastle, Newcastle, NSW 2308, Australia.
Kylie A AbbottNutraceuticals Research Program, School of Biomedical Sciences & Pharmacy, University of Newcastle, Newcastle, NSW 2308, Australia.
Jessica J A FergusonNutraceuticals Research Program, School of Biomedical Sciences & Pharmacy, University of Newcastle, Newcastle, NSW 2308, Australia.
Martin VeyseySchool of Medicine & Public Health, University of Newcastle, Newcastle, NSW 2308, Australia.
Mark LucockSchool of Environmental & Life Sciences, University of Newcastle, Newcastle, NSW 2308, Australia.
Suzanne NiblettSchool of Medicine & Public Health, University of Newcastle, Newcastle, NSW 2308, Australia.
Katrina KingSchool of Medicine & Public Health, University of Newcastle, Newcastle, NSW 2308, Australia.ORCID 0000-0002-2015-0298
Manohar L GargNutraceuticals Research Program, School of Biomedical Sciences & Pharmacy, University of Newcastle, Newcastle, NSW 2308, Australia. manohar.garg@newcastle.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate whether a novel physiologically relevant marker, InsuTAG (fasting insulin × fasting triglycerides) can predict insulin resistance (IR) and metabolic syndrome (MetS). Data of 618 participants from the Retirement Health and Lifestyle Study (RHLS) were evaluated for the current study. IR was defined by homeostatic model assessment (HOMA-IR) scores. Pearson correlations were used to examine the associations of InsuTAG with HOMA-IR and other markers. Predictions of IR from InsuTAG were evaluated using multiple regression models. Receiver operating characteristic curves (ROC) were constructed to measure the sensitivity and specificity of InsuTAG values and to determine the optimum cut-off point for prediction of IR. InsuTAG was positively correlated with HOMA-IR (r = 0.86; p < 0.0001). InsuTAG is a strong predictor of IR accounting for 65.0% of the variation in HOMA-IR values after adjusting for potential confounders. Areas under the ROC curve showed that InsuTAG (0.93) has higher value than other known lipid markers for predicting IR, with a sensitivity and specificity of 84.15% and 86.88%. Prevalence of MetS was significantly (p < 0.0001) higher in subjects with InsuTAG values greater than optimal cut-off value of 11.2. Thus, InsuTAG appears to be a potential feasible marker of IR and metabolic syndrome.

Indexed as

Decision Support TechniquesInsulin ResistanceAgedAged, 80 and overAustraliaFemaleHumansInsulinMaleMetabolic SyndromePrevalenceROC CurveSensitivity and SpecificityTriglyceridesInsulinTriglycerides

Identifiers

PMID29123160
PMCPMC5680177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.